Novaliq Announces First Patient Randomized in the Phase 3 tria...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
HEIDELBERG, Germany, Dec 8 /PRNewswire-AsiaNet/ -- - ESSENCE-2 is the second registration trial to complete the clinical development of CyclASol® as agreed with U.S. Food and Drug Administration (FDA)- Designed to replicate efficacy demonstrated in previous phase 2/3 ESSENCE-1 trial - Topl...
Authors: LATEST ASIANET NEWS RELEASES